Journals / İstanbul Tıp Fakültesi Dergisi / 2022 / Cilt: 85 - Sayı: 1

FACTORS PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER

LOKAL İLERİ MİDE KANSERİNDE NEOADJUVAN KEMOTERAPİYE YANITI ÖNGÖREN FAKTÖRLER

Pages
41–50
Publication Date
2022-01-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objective: In the treatment of local advanced gastric cancer (LAGC), it is recommended to start with neoadjuvant chemotherapy (NAC).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In the treatment of local advanced gastric cancer (LAGC), it is recommended to start with neoadjuvant chemotherapy (NAC).
📊
Key Findings & Data:Material and Method: A retrospective examination was made of 38 patients who underwent surgery for LAGC after receiving NAC.
💡
Conclusion & Impact:Although not at a statistically significant level, there was also observed to be a poor response to chemotherapy in the presence of low grade and lymphovascular invasion.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lokal ileri mide kanseri · neoadjuvan kemoterapi yanıtı · patolojik tam yanıt

Abstract

Objective: In the treatment of local advanced gastric cancer (LAGC), it is recommended to start with neoadjuvant chemotherapy (NAC). Although the benefits of NAC have been shown, it is still not fully understood which patients respond better. The aim of this study was to investigate the effect of hematological and histopathological parameters on the response to chemotherapy. Material and Method: A retrospective examination was made of 38 patients who underwent surgery for LAGC after receiving NAC. Evaluations were made by comparing the demographic characteristics, histopathological characteristics in an endoscopic biopsy of the tumor, preoperative hemoglobin levels, and neutrophil-lymphocyte ratios with the postoperative pathological response to determine which tumor characteristics gave a better response. Results: In the postoperative histopathological evaluation, there was a pathological complete response to chemotherapy in two patients (6%), grade 1 in 9 patients (24%), grade 2 in 13 patients (34%), and grade 3 in 14 patients (36%). A statistically significant relationship was determined between the histopathological absence of perineural invasion and pathological complete response (p=0.023). Conclusion: A relationship between perineural invasion and poor response to chemotherapy was determined. Although not at a statistically significant level, there was also observed to be a poor response to chemotherapy in the presence of low grade and lymphovascular invasion.

Özet

Amaç: Lokal ileri mide kanserinde (LİMK) tedaviye neoadjuvan kemoterapi (NAK) ile başlanması önerilir. Ancak NAK’nin faydaları gösterilmiş olsa da hangi hasta gurubunun tedaviye daha iyi yanıt verdiği tam olarak anlaşılamamıştır. Çalışmamızda hematolojik ve histopatolojik parametrelerin kemoterapi yanıtı üzerine etkisi araştırılmıştır. Yöntem ve Gereç: Bu çalışmada lokal ileri evre mide kanseri nedeni ile neoadjuvan kemoterapi görüp sonrasında ameliyat edilen 38 hasta retrospektif olarak incelendi. Ameliyat sonrası patolojik yanıt ile hastanın demografik özellikleri, tümörün endoskopik biyopsideki histopatolojik özellikleri, preoperatif hemoglobin seviyesi, nötrofil lenfosit oranı karşılaştırılıp hangi özellikteki tümörlerin daha iyi yanıt verdiği değerlendirildi. Bulgular: Ameliyat sonrası yapılan histopatolojik değerlendirmede 2 (%6) hastada patolojik tam yanıt, 9 (%24) hastada grade 1 yanıt, 13 (%34) hastada grade 2 yanıt ve 14 hastada (%36) grade 3 yanıt mevcuttu. Patolojik tam yanıt ile histopatolojik olarak perinöral invazyon olmaması istatistiksel olarak anlamlı ilişki gösterdi (p=0.023). Sonuç: Çalışmamızda NAK alan LİMK’li hastalarda perinöral invazyon varlığının kemoterapiye kötü yanıt ile ilişkisi olduğu görülmüştür. Ayrıca lenfovaskular invazyon ve düşük grade mevcudiyetinde istatistiksel olarak anlamlı olmasa da kemoterapiye kötü yanıt gözlenmiştir.

🔖

Cite This Article

YILDIRIM, E., BEKTAŞ, S., AYDIN, S. G., ER, A. M., YANIK, İ., GÜMÜŞKAYA, P. Ö., YILMAZ, B. U., BİLİCİ, A., ONCEL, M. (2022). FACTORS PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER. İstanbul Tıp Fakültesi Dergisi, Cilt: 85 - Sayı: 1, 41–50. https://ajindex.com/articles/373221

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018
  2. 68(6):394-424. [CrossRef] 2. Kikuchi S, Katada N, Sakuramoto S, Kobayashi N, Shimao H, Watanabe M, et al. Survival after surgical treatment of early gastric cancer: surgical techniques and long-term survival. Langenbecks Arch Surg 2004
  3. 389(2):69-74. [CrossRef] 3. Lu J, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, et al. Consideration of tumor size improves the accuracy of TNM predictions in patients with gastric cancer after curative gastrectomy. Surg Oncol 2013
  4. 22(3):167-71. [CrossRef] 4. Gee DW, Rattner DW. Management of gastroesophageal tumors. Oncologist 2007
  5. 12(2):175-85. [CrossRef] 5. Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016
  6. 14(10):1286-312. [CrossRef] 6. Stewart C, Chao J, Chen YJ, Lin J, Sullivan MJ, Melstrom L, et al. Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. Transl Gastroenterol Hepatol 2019
  7. [CrossRef] 7. Wang XZ, Zeng ZY, Ye X, Sun J, Zhang ZM, Kang WM. Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol 2020
  8. 12(1):37-53. [CrossRef] 8. Cao LL, Lu J, Li P, Xie JW, Wang JB, Lin JX, et al. Evaluation of the Eighth Edition of the American Joint Committee on Cancer TNM Staging System for Gastric Cancer: An Analysis of 7371 Patients in the SEER Database. Gastroenterol Res Pract 2019
  9. 6294382. [CrossRef] 9. Yamamura Y, Nakajima T, Ohta K, Nashimoto A, Arai K, Hiratsuka M, et al. Determining prognostic factors for gastric cancer using the regression tree method. Gastric Cancer 2002
  10. 5(4):201-7. [CrossRef] 10. Yokota T, Ishiyama S, Saito T, Teshima S, Narushima Y, Murata K, et al. Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol 2004
  11. 39(4):380-4. [CrossRef] 11. Bu Z, Zheng Z, Li Z, Zhang L, Wu A, Wu X, et al. Lymphatic vascular invasion is an independent correlated factor for lymph node metastasis and the prognosis of resectable T2 gastric cancer patients. Tumour Biol 2013
  12. 34(2):1005-12. [CrossRef] 12. Li Z, Shan F, Wang Y, Zhang Y, Zhang L, Li S, et al. Correlation of pa